Hexagon Composites ASA
On 18 February 2021, Flakk Gruppen AS purchased 250,000 shares in Hexagon Purus AS ("Hexagon Purus" or "the Company") at an average price of NOK 53.8497 per share. Flakk Gruppen AS is a company controlled by Knut Flakk, Chairman of the Board of Directors of Hexagon Composites ASA.
Following the transaction, Flakk Gruppen AS holds 818,274 shares in Hexagon Purus AS, and the total shareholding in Hexagon Purus of Knut Flakk and his close associates is 4,698,587 shares.
For further information, please contact:
Salman Alam, Vice President Corporate Development, Hexagon Purus
Telephone: +47 476 12 713 | salman.alam@hexagonpurus.com
Karen Romer, SVP Communications, Hexagon Composites
Telephone: +47 950 74 950 | karen.romer@hexagongroup.com
About Hexagon Purus
Hexagon Purus, a Hexagon Composites company, is a world leading provider of hydrogen type 4 high-pressure cylinders, battery packs and vehicle systems integration for fuel cell electric and battery electric vehicles. Hexagon Purus enables zero emission solutions for light, medium and heavy-duty vehicles, buses, ground storage, distribution, maritime, rail, aerospace and backup power solutions.
For more information, please visit hexagonpurus.com.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Broad Arrow Auctions8.1.2026 10:30:00 CET | Press release
MICHAEL SCHUMACHER’S FIRST F1 GRAND PRIX-WINNING 1992 BENETTON B192-05 TO STAR IN BROAD ARROW’S GLOBAL ICONS: EUROPE ONLINE AUCTION
Alkane Resources Limited8.1.2026 10:22:32 CET | Press release
December 2025 Quarterly Production Update
Onco3R Therapeutics BV8.1.2026 09:00:00 CET | Press release
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics
Santhera Pharmaceuticals Holding AG8.1.2026 08:16:03 CET | Press release
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
CMR Surgical8.1.2026 08:03:26 CET | Press release
CMR Surgical receives CE Mark for use of Versius in paediatric surgery
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
